Auris Medical's Bentrio Nasal Spray Shows Encouraging Preclinical Action In Prevention, Mitigation Of COVID-19

Auris Medical Holding Ltd (NASDAQ:EARS) has announced additional preclinical data in a primary human nasal airway epithelium model from its Bentrio (AM-301) nasal spray for COVID-19.
AM-301 was found to be safe in vitro, and it significantly decelerated viral titer growth in experimental models of prophylaxis and mitigation.
The manuscript of the preclinical data is available here.
Prophylactic treatment with AM-301 was protective against SARS-CoV-2 infection. The daily application of the product starting 10 minutes before inoculation led to a 2-log (99%) reduction in viral titer by Day 4 compared to controls.
Inserts that received the product daily, starting 24 or 30 hours after viral infection, also had a lower viral titer, corresponding to a 12- or 14-fold lower TCID50 at the end of the treatment.
The time profile of SARS-CoV-2 infection was significantly decelerated compared to controls both in the case of prophylactic treatment and in the case of mitigation treatment starting 24 or 30 hours post-infection.
Price Action: EARS shares are up 1.61% at $3.22 during the market session on the last check Wednesday.